2024
Assessment of immune cells in the uterine fluid at the time of the embryo transfer
Strbo N, Rodriguez S, Padula L, Fisher E, Lyons A, Rodriguez C, Rivas K, Ibrahim M, Paidas M, Attia G. Assessment of immune cells in the uterine fluid at the time of the embryo transfer. American Journal Of Reproductive Immunology 2024, 91: e13842. PMID: 38650366, DOI: 10.1111/aji.13842.Peer-Reviewed Original ResearchConceptsGamma delta T cellsFrozen embryo transferLower uterusAssisted reproductive technologyIn vitro fertilizationTransfer catheterT cellsEmbryo transferTime of implantationImmune milieuUpper uterusImmune cellsUltrasound guidanceExpression of CD4+ T cellsAssessment of immune cellsImprove IVF outcomesCD8+ T cellsCD4+ T cellsPopulation of T cellsComposition of immune cellsLower uterine segmentTime of embryo transferExpression of CD3+T regulatory cellsCD3+ cells
2014
Combined hormonal contraception and risk of venous thromboembolism within the first year following pregnancy
Petersen J, Bergholt T, Nielsen A, Paidas M, Løkkegaard E. Combined hormonal contraception and risk of venous thromboembolism within the first year following pregnancy. Thrombosis And Haemostasis 2014, 112: 73-78. PMID: 24499991, DOI: 10.1160/th13-09-0797.Peer-Reviewed Original ResearchConceptsVenous thromboembolismHormonal contraceptivesIncidence ratiosFirst-time venous thromboembolismCrude incidence ratioCombined oral contraceptivesNationwide retrospective cohortConfirmed pregnanciesOral contraceptivesRetrospective cohortHormonal contraceptionPuerperal periodAbsolute riskWeeks postpartumDanish womenMAIN OUTCOMEThromboembolismPregnancyContraceptivesOne-yearUnique registryFirst yearRiskBirthRegistry
2013
Exploring the Role of Antithrombin Replacement for the Treatment of Preeclampsia: A Prospective Randomized Evaluation of the Safety and Efficacy of Recombinant Antithrombin in Very Preterm Preeclampsia (PRESERVE‐1)
Paidas MJ, Sibai BM, Triche EW, Frieling J, Lowry S, Group T. Exploring the Role of Antithrombin Replacement for the Treatment of Preeclampsia: A Prospective Randomized Evaluation of the Safety and Efficacy of Recombinant Antithrombin in Very Preterm Preeclampsia (PRESERVE‐1). American Journal Of Reproductive Immunology 2013, 69: 539-544. PMID: 23444920, DOI: 10.1111/aji.12091.Peer-Reviewed Original ResearchConceptsProspective Randomized EvaluationAntithrombin replacementWeeks' gestationRandomized EvaluationRecombinant antithrombinTreatment of preeclampsiaRecombinant human ATExpectant managementPreterm preeclampsiaPrimary endpointMaternal indicationsGestational ageStudy enrollmentAT therapyPreeclampsia studyPreeclampsiaGestationHuman ATAT replacementPharmacokinetic activityAntithrombinEfficacySafetyLaboratory assaysDelivery
2010
Mortality of mothers from cardiovascular and non‐cardiovascular causes following pregnancy complications in first delivery
Lykke JA, Langhoff‐Roos J, Lockwood CJ, Triche EW, Paidas MJ. Mortality of mothers from cardiovascular and non‐cardiovascular causes following pregnancy complications in first delivery. Paediatric And Perinatal Epidemiology 2010, 24: 323-330. PMID: 20618721, DOI: 10.1111/j.1365-3016.2010.01120.x.Peer-Reviewed Original ResearchConceptsNon-cardiovascular causesGestational age offspringEarly maternal deathPreterm deliveryCardiovascular causesHypertensive disordersPregnancy complicationsMaternal deathsEarly deathRegistry-based retrospective cohort studyCox proportional hazards modelFirst singleton deliveryMortality of mothersRetrospective cohort studyProportional hazards modelDenmark 1978Placental abruptionCohort studySingleton deliveriesLarge cohortFirst deliveryMortality hazardHazards modelSubsequent deathStrong marker
2009
Preterm delivery and risk of subsequent cardiovascular morbidity and type‐II diabetes in the mother
Lykke J, Paidas M, Damm P, Triche E, Kuczynski E, Langhoff‐Roos J. Preterm delivery and risk of subsequent cardiovascular morbidity and type‐II diabetes in the mother. BJOG An International Journal Of Obstetrics & Gynaecology 2009, 117: 274-281. PMID: 20015308, DOI: 10.1111/j.1471-0528.2009.02448.x.Peer-Reviewed Original ResearchConceptsRisk of thromboembolismType II diabetesPreterm deliveryCardiovascular morbiditySingleton deliveriesRegistry-based retrospective cohort studyCox proportional hazards modelFirst singleton deliveryHypertensive pregnancy disordersMaternal cardiovascular morbiditySecond singleton deliverySpecific cardiovascular eventsSubsequent cardiovascular morbidityRetrospective cohort studyIschemic heart diseaseWeeks of gestationYear of deliveryProportional hazards modelFetal growth deviationsMaternal hypertensionAdjusted riskCardiovascular eventsPlacental abruptionPregnancy complicationsCohort studyHypertensive Pregnancy Disorders and Subsequent Cardiovascular Morbidity and Type 2 Diabetes Mellitus in the Mother
Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. Hypertensive Pregnancy Disorders and Subsequent Cardiovascular Morbidity and Type 2 Diabetes Mellitus in the Mother. Hypertension 2009, 53: 944-951. PMID: 19433776, DOI: 10.1161/hypertensionaha.109.130765.Peer-Reviewed Original ResearchMeSH KeywordsAdultCardiovascular DiseasesCase-Control StudiesCohort StudiesDenmarkDiabetes Mellitus, Type 2FemaleHumansHypertension, Pregnancy-InducedIncidencePre-EclampsiaPregnancyPregnancy OutcomePregnancy RatePregnancy, High-RiskPremature BirthProbabilityProportional Hazards ModelsRegistriesSeverity of Illness IndexYoung AdultConceptsType 2 diabetes mellitusSubsequent type 2 diabetes mellitusHypertensive pregnancy disordersSubsequent cardiovascular eventsDiabetes mellitusGestational hypertensionSevere preeclampsiaPregnancy disordersSubsequent hypertensionCardiovascular eventsRegistry-based cohort studyConsecutive singleton deliveriesSubsequent cardiovascular morbidityCongestive heart failureIschemic heart diseaseCardiovascular morbidityPlacental abruptionPreterm deliveryThromboembolic eventsCohort studyMild preeclampsiaSingleton deliveriesHeart failureSubsequent thromboembolismGestational age
2005
Protein Z, protein S levels are lower in patients with thrombophilia and subsequent pregnancy complications
PAIDAS MJ, KU D, LEE M, MANISH S, THURSTON A, LOCKWOOD CJ, ARKEL YS. Protein Z, protein S levels are lower in patients with thrombophilia and subsequent pregnancy complications. Journal Of Thrombosis And Haemostasis 2005, 3: 497-501. PMID: 15748239, DOI: 10.1111/j.1538-7836.2005.01158.x.Peer-Reviewed Original ResearchConceptsAdverse pregnancy outcomesNormal pregnancy outcomeProtein S levelsPZ levelsPregnancy outcomesProtein SSubsequent pregnancy complicationsProtein ZAdditional risk factorsFree PS antigenPregnancy complicationsPregnant controlsThird trimesterPlasma levelsRisk factorsPatientsThrombophiliaPS antigenS levelsWomenSignificant decreasePS levelsOutcomesLow levelsTrimester
2004
Does heparin therapy improve pregnancy outcome in patients with thrombophilias?
Paidas M, Ku D, Triche E, Lockwood C, Arkel Y. Does heparin therapy improve pregnancy outcome in patients with thrombophilias? Journal Of Thrombosis And Haemostasis 2004, 2: 1194-1195. PMID: 15219211, DOI: 10.1111/j.1538-7836.2004.00784.x.Peer-Reviewed Original ResearchSoluble monocyte cluster domain 163, a new global marker of anti‐inflammatory response, is elevated in the first trimester of pregnancy
Paidas M, Ku D, Davis B, Lockwood C, Arkel Y. Soluble monocyte cluster domain 163, a new global marker of anti‐inflammatory response, is elevated in the first trimester of pregnancy. Journal Of Thrombosis And Haemostasis 2004, 2: 1009-1010. PMID: 15140143, DOI: 10.1111/j.1538-7836.2004.00681.x.Peer-Reviewed Original Research
2002
The use of coagulation activation markers (soluble fibrin polymer, TpPTM, prothrombin fragment 1.2, thrombin–antithrombin, and D-dimer) in the assessment of hypercoagulability in patients with inherited and acquired prothrombotic disorders
Arkel Y, Paidas M, Ku D. The use of coagulation activation markers (soluble fibrin polymer, TpPTM, prothrombin fragment 1.2, thrombin–antithrombin, and D-dimer) in the assessment of hypercoagulability in patients with inherited and acquired prothrombotic disorders. Blood Coagulation & Fibrinolysis 2002, 13: 199-205. PMID: 11943933, DOI: 10.1097/00001721-200204000-00005.Peer-Reviewed Original ResearchMeSH KeywordsActivated Protein C ResistanceAdolescentAdultAgedAged, 80 and overAntiphospholipid SyndromeAntithrombin IIIAntithrombin III DeficiencyAutoimmune DiseasesBiomarkersEnzyme-Linked Immunosorbent AssayFactor VFemaleFibrinFibrin Fibrinogen Degradation ProductsHumansHyperhomocysteinemiaMaleMiddle AgedPeptide FragmentsPeptide HydrolasesProtein C DeficiencyProtein S DeficiencyProthrombinRiskSolubilityThrombophiliaConceptsCoagulation activation markersActivation markersAssessment of hypercoagulabilityPercentage of patientsProthrombotic disordersVascular eventsConsecutive patientsThrombophilic abnormalitiesThrombotic riskPatientsSoluble fibrin polymersTPP levelsMean levelsMarkersAbnormalitiesFibrin polymersHypercoagulability
2000
Change in Cervical Length After Cerclage as a Predictor of Preterm Delivery
DIJKSTRA K, FUNAI E, O'NEILL L, REBARBER A, PAIDAS M, YOUNG B. Change in Cervical Length After Cerclage as a Predictor of Preterm Delivery. Obstetrics And Gynecology 2000, 96: 346-350. DOI: 10.1097/00006250-200009000-00006.Peer-Reviewed Original ResearchConceptsCervical lengthProphylactic cerclagePregnancy outcomesWeeks' gestationSerial cervical length measurementsMean cervical lengthMethods Eighty womenTransvaginal ultrasonographic evaluationCervical length measurementEarly third trimesterTransvaginal ultrasound examinationCerclage groupPreterm deliveryPreterm birthSerial followTerm deliveryPrimary physicianThird trimesterUltrasonographic evaluationUltrasound examinationCerclageMost womenPatientsGestationSignificant associationChange in cervical length after cerclage as a predictor of preterm delivery.
Dijkstra K, Funai E, O'Neill L, Rebarber A, Paidas M, Young B. Change in cervical length after cerclage as a predictor of preterm delivery. Obstetrics And Gynecology 2000, 96: 346-50. PMID: 10960624, DOI: 10.1016/s0029-7844(00)00924-8.Peer-Reviewed Original ResearchConceptsCervical lengthProphylactic cerclagePregnancy outcomesWeeks' gestationSerial cervical length measurementsMean cervical lengthTransvaginal ultrasonographic evaluationCervical length measurementEarly third trimesterTransvaginal ultrasound examinationCerclage groupPreterm deliveryPreterm birthSerial followTerm deliveryPrimary physicianThird trimesterUltrasonographic evaluationUltrasound examinationCerclageMost womenPatientsGestationSignificant associationLogistic regression
1999
Change in Cervical Length After Prophylactic Cerclage
FUNAI E, PAIDAS M, REBARBER A, O'NEILL L, ROSEN T, YOUNG B. Change in Cervical Length After Prophylactic Cerclage. Obstetrics And Gynecology 1999, 94: 117-119. DOI: 10.1097/00006250-199907000-00023.Peer-Reviewed Original ResearchConceptsCervical lengthInstitutional review boardProphylactic cerclageShirodkar sutureIncompetent cervixMethods PatientsTerm deliveryTransvaginal ultrasoundObservational studyResults TwentyPhysician preferenceReview boardMcDonald operationsCerclageFurther studiesMeasurable increaseShirodkarCervixPatientsChange in cervical length after prophylactic cerclage.
Funai E, Paidas M, Rebarber A, O'Neill L, Rosen T, Young B. Change in cervical length after prophylactic cerclage. Obstetrics And Gynecology 1999, 94: 117-9. PMID: 10389730, DOI: 10.1016/s0029-7844(98)00568-7.Peer-Reviewed Original Research
1998
Fetal Splenic Size in Anemia Due to Rh-alloimmunization
BAHADO-SINGH R, OZ U, MARI G, JONES D, PAIDAS M, ONDEROGLU L. Fetal Splenic Size in Anemia Due to Rh-alloimmunization. Obstetrics And Gynecology 1998, 92: 828-832. DOI: 10.1097/00006250-199811000-00017.Peer-Reviewed Original ResearchConceptsSevere anemiaPrior transfusionsHemoglobin deficitSplenic enlargementCircumference valuesPrediction of anemiaMean hemoglobin concentrationReceiver operator characteristic curveCross-sectional normative dataOperator characteristic curveSensitized casesSingleton pregnanciesFetal anemiaGestational ageNormal medianRh alloimmunizationSplenic sizeSplenic lengthSingleton fetusesAbdominal circumferenceExtramedullary erythropoiesisFetal abdomenNormal groupAnemiaHemoglobin concentration